Rotaviruses are the major cause of severe gastroenteritis in young children worldwide. Vaccines are being developed to reduce the huge impact of the disease caused by rotavirus infection. The first vaccines were developed to provide specific protection against the four predominant serotypes of rotavirus, G1 to G4 (29), as these have been the most common serotypes causing severe disease in children globally since 1973 (40). Recent epidemiological studies in Bangladesh (49), Brazil (23, 32, 44), India (1), the United States (24, 42), and Malawi (13) show that other G types (G5, G6, G8, G9, and G10) can be identified as causes of severe disease and are of emerging importance in some communities. Serotype G9 is recognized as the most widespread of the "emerging" serotypes and has been identified since 1996 as a frequent cause of severe disease in hospitalized children in the United States, Japan, India, Bangladesh, France, Italy, Malawi, Nigeria, Australia, China, Thailand, and the United Kingdom (3,7,8,12,19,26,34,37,39,41,42,47,49,50).The rotavirus genome is composed of 11 segments of double-stranded RNA located inside the core of a triple-layered structure. The outer capsid proteins VP4 and VP7 elicit neutralizing antibody immune responses, creating both serotypespecific and cross-reactive immunity (18). Antigenic differences in VP4 and VP7 are the basis of the G (VP7 glycoprotein) and P (protease-activated VP4 protein) serotypes. To date, 9 P and 10 G serotypes have been identified in humans by cross-neutralization tests (18,46,48). Unlike rotavirus G typing, there are two designations of rotavirus type P because of incomplete agreement between the P serotype (based on enzyme immunoassay [EIA] reactivities) and the P genotype (based on sequence similarity). The P genotypes are in brackets, whereas the P serotypes are open numbers. Epidemiological studies have shown that serotypes G1, G2, G3, and G4, associated with P1A (8) or P1B (4), have been the most common serotypes causing severe disease in children globally over the last 20 years (35,40). Genetic and antigenic variation has been recorded within the G1, G2, G3, and G4 serotypes (38). There is evidence that G9 strains are more susceptible to reassortment, and hence to genetic change, than are these other serotypes (27,49). The increasing prevalence of G9 strains worldwide makes it important to continue molecular epidemiological studies of their occurrence and genetic and antigenic variability.The emergence and persistence of serotype G9 has had a major impact on health care services in Australia (33,34). This